Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer

Median OS Not Yet Reached In PD-L1-Positive Patients

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.